Cure Alzheimer's Fund Cure Alzheimer's Fund

GABAergic inhibitory efficiency and adult neurogenesis in the hippocampus of aged Ts65Dn mice, a model of ‘Alzheimer’s disease in Down syndrome’, after chronic treatment with the monoacylglycerol lipase inhibitor JZL184

2014

Recently we observed that chronic suppression of monoacylglycerol lipase with the selective blocker JZL184 increased brain levels of endocannabinoid 2-arachidonoil glycerol (2-AG), restored long-term potentiation, improved cognition, and reduced brain levels of Aβ40 and Aβ42 in aged Ts65Dn mice, a model of ‘Alzheimer’s disease in Down syndrome’ (ADDS). In this proposal, we plan to examine the mechanisms responsible for the restoration of cognition and synaptic plasticity in the ADDS model mice. We suggest that two types of changes resulting from JZL184-treatment may contribute synergistically to the improvements in cognition and synaptic plasticity: (I) An increase of the level of 2-AG may result in a reduction of efficiency of the inhibitory GABAergic neurotransmission and, possibly, in improvement of adult neurogenesis. (II) The decrease of hippocampal levels of Aβ40 and Aβ42, which may reduce inhibitory efficiency and improve synaptic plasticity.

Working Hypothesis: Enhancement of synaptic plasticity and cognition in aged Ts65Dn mice by chronic blockade of monoacylglycerol lipase (MAGL) is caused by persistent alterations in properties of GABAergic synapses and changes in adult neurogenesis.

Foundational Production of New Animal/Cellular Models of AD William C. Mobley

Funding to Date

$100,000

Focus

Foundational, Production of New Animal/Cellular Models of AD

Researchers

William C. Mobley, M.D., Ph.D.

Related Content:


Systematic Assessment of Tandem Repeats in Alzheimer’s Disease (STaR-AD) Lars Bertram Valerija Dobricic 2024-02-28 Interpreting Alzheimer’s Disease-Associated Genetic Variation at Enhancer Regions Andreas R. Pfenning 2024-02-01 Moving the Cure Alzheimer’s Fund Genome Project Beyond Simple Associations: Integrating Functional Information, Fine-Mapping and Causal Inference Approaches into the Family-Based Analysis of the Cure Alzheimer’s Fund Whole-Genome Sequencing (WGS) Family Study Christoph Lange 2024-02-01 Characterization and Validation of Two Recently Created Sheep Models of Alzheimer’s Disease in Preparation for Use as a Preclinical Pharmaceutical Testing Model Russell G. Snell Natasha McKean 2024-01-31 Utility of Blood-Based Markers for Predicting Amyloid-Related Imaging Abnormalities and Their Course in Mild Cognitive Impairment and Alzheimer’s Disease Subjects Undergoing Routine Clinical Treatment with Amyloid-Directed Antibodies P. Murali Doraiswamy 2024-01-12 APP Gene Dose-Mediated Dysregulation of the Endolysosomal Network Acts to Compromise Synaptic Structure and Function Leading to Alzheimer’s Disease in Down Syndrome William C. Mobley 2023-12-21 Growth, Characterization and Distribution of a Neurodegenerative Disease-Focused Fibroblast/iPS Cell Bank to Support Molecular Models of Patient-Specific Variation with Validation in Matched Donated Brain Tissues Derek H. Oakley 2023-12-08 Multidisciplinary Phenotyping of a Novel Humanized LOAD Mouse Model Giuseppina Tesco 2023-10-25